Back to top
more

INC Research Holdings, Inc. (SYNH)

(Delayed Data from NSDQ)

$47.27 USD

47.27
483,054

+0.56 (1.20%)

Updated May 3, 2019 04:00 PM ET

After-Market: $47.36 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Syneos Health (SYNH) Declares Strategic Partnership With Oracle

Syneos Health (SYNH) announces an expanded collaboration with Oracle to accelerate patient recruitment capabilities.

Syneos Health (SYNH) Expands Catalyst Site Program to China

Syneos Health (SYNH) announces a collaboration with China's Wuhan Union Hospital, expanding clinical trial capabilities.

Syneos Health (SYNH) to Go Private, Reports Q2 Performance

Syneos Health (SYNH) announces shareholders' approval for the impending merger and releases second-quarter 2023 financial results.

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 12.33% and 0.33%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Sonendo, Inc. (SONX) Reports Q2 Loss, Misses Revenue Estimates

Sonendo, Inc. (SONX) delivered earnings and revenue surprises of -26.67% and 0.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Schrodinger, Inc. (SDGR) Report Negative Earnings Next Week? What You Should Know

Schrodinger, Inc. (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Syneos Health (SYNH) Q2 Earnings Expected to Decline

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Syneos Health (SYNH) Collaborates With uMotif for New Platform

Syneos Health (SYNH) partners with uMotif to deliver the patient-centric eClinical platform.

Syneos Health (SYNH) Down 0.1% Since Last Earnings Report: Can It Rebound?

Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Syneos Health (SYNH) Sell-Off Appears Strategic Amid Margin Woes

Syneos Health's (SYNH) purchase price represents a 24% premium to its unaffected closing stock price prior to the announcement. Margin pressure continues to weigh on the stock.

Syneos Health (SYNH) Tops Q1 Earnings, Announces Merger Plan

Syneos Health's (SYNH) first-quarter 2023 earnings and revenues beat estimates. The company enters into a definitive merger agreement to be acquired by a private investment consortium.

Syneos Health (SYNH) Announces a $7.1 Billion Merger Agreement

Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.

Syneos Health (SYNH) Q1 Earnings and Revenues Surpass Estimates

Syneos Health (SYNH) delivered earnings and revenue surprises of 11.94% and 6.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Computer Programs and Systems (CPSI) Misses Q1 Earnings Estimates

Computer Programs and Systems (CPSI) delivered earnings and revenue surprises of -23.68% and 2.05%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Investors Should Retain Syneos Health (SYNH) for Now

Syneos Health's (SYNH) share price movement is expected to be favorable due to the strength of the company's Syneos One portfolio and several value-added partnership deals.

Autolus (AUTL) Selects Cardinal Health for Cell Therapy Supply

Autolus (AUTL) partners with Cardinal Health to bring next-generation CAR-T cell therapies to the market and revolutionize cancer treatment.

NextGen's (NXGN) Behavioral Health Suite Adopted by Mindful Care

NextGen's (NXGN) Behavioral Health Suite is expected to facilitate Mindful Care's ability to offer same-day appointments via online scheduling.

MedTech Bigwigs in Spotlight as AI Revolutionizes Healthcare

MedTech player like Medtronic (MDT) are integrating artificial intelligence (AI) capabilities to aid therapeutic and diagnostic applications.

Syneos Health (SYNH) Partners With KX for Data-Driven Insights

Syneos Health's (SYNH) partnership with KX is likely to accelerate clinical trial execution using AI-enabled solutions.

Syneos Health's (SYNH) New Microsoft Deal to Expand AI Usage

With the multi-year deal, Syneos Health (SYNH) aims to deliver technology and data solutions with Microsoft.

Syneos Health's (SYNH) Product Launch Aids, FX Woe Hurts

Syneos Health (SYNH) remains confident about the long-term strength of its business, given its robust backlog and unique market position.

Syneos Health (SYNH) Q4 Earnings Beat Estimates, Margins Down

Higher reimbursable expenses and growth in Deployment Solutions contribute to Commercial Solutions revenue growth at Syneos Health (SYNH).

Syneos Health (SYNH) Tops Q4 Earnings and Revenue Estimates

Syneos Health (SYNH) delivered earnings and revenue surprises of 4.24% and 5.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Syneos Health (SYNH) Q4 Earnings Expected to Decline

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Syneos Health (SYNH) Signs New Partnership With Cryoport

Syneos Health (SYNH) inks a partnership with Cryoport to deliver seamless integration and insights for key services for cell and gene trial operations to biopharmaceutical customers.